Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2.
Liang Y, Zhang J, Yuan RY, Wang MY, He P, Su JG, Han ZB, Jin YQ, Hou JW, Zhang H, Zhang XF, Shao S, Hou YN, Liu ZM, Du LF, Shen FJ, Zhou WM, Xu K, Gao RQ, Tang F, Lei ZH, Liu S, Zhen W, Wu JJ, Zheng X, Liu N, Chen S, Ma ZJ, Zheng F, Ren SY, Hu ZY, Huang WJ, Wu GZ, Ke CW, Li QM. Liang Y, et al. Among authors: li qm. Cell Discov. 2022 Feb 15;8(1):17. doi: 10.1038/s41421-022-00383-5. Cell Discov. 2022. PMID: 35169113 Free PMC article.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: li m, li qm. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: li m, li qm. Nat Commun. 2022 Jun 27;13(1):3654. doi: 10.1038/s41467-022-31379-0. Nat Commun. 2022. PMID: 35760812 Free PMC article. Clinical Trial.
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J, Han ZB, Liang Y, Zhang XF, Jin YQ, Du LF, Shao S, Wang H, Hou JW, Xu K, Lei W, Lei ZH, Liu ZM, Zhang J, Hou YN, Liu N, Shen FJ, Wu JJ, Zheng X, Li XY, Li X, Huang WJ, Wu GZ, Su JG, Li QM. Zhang J, et al. Among authors: li xy, li x, li qm. Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633. Elife. 2022. PMID: 36004719 Free PMC article.
304 results